Every Form 4 that Madrigal Pharmaceuticals, Inc. (MDGL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDGL filings page.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported that President and CEO William John Sibold sold 11,583 shares of common stock in 24 open-market transactions on September 9 and 11, 2026. Sales on September 9 were made by the issuer on his behalf to cover tax withholding from vesting restricted stock units, and were automatic. Sales on September 11 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported that officer Kelley T. Shannon, General Counsel, had 664 shares of common stock sold on 2026-08-17 at $514.97 per share. According to the company’s disclosure, the shares were sold by the issuer on her behalf solely to cover tax withholding obligations from vesting restricted stock units and were automatic, not at her discretion. Following this transaction, she directly holds 11,474 MDGL common shares.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported equity compensation grants to director John C. Reed. He received 647 shares of Common Stock as restricted stock units that vest 50% on August 15, 2027 and 50% on August 15, 2028, subject to continued service. He also received a stock option for 1,078 shares at an exercise price of $507.56 per share, expiring August 15, 2036, vesting 50% on August 15, 2027 and 12.5% at the end of each successive three-month period for four periods thereafter, contingent on continued service.
Madrigal Pharmaceuticals President and CEO William John Sibold earned 50,000 shares of common stock on July 17, 2026 after meeting performance and service conditions under a one-time sign-on Performance RSU award. On July 20, 2026, the issuer sold 2,500 of these shares on his behalf in multiple automatic transactions at weighted-average prices between $542.22 and $555.10 per share to cover tax withholding obligations, and these sales were not at Sibold's discretion. The company is irrevocably obligated to issue the remaining earned shares to him on September 8, 2029.
Madrigal Pharmaceuticals director Rebecca Taub reported new equity awards. She received 454 restricted stock units that vest on the earlier of June 17, 2027 or the company’s 2027 annual meeting, if she remains in service. She was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share, expiring on June 17, 2036, with the same vesting schedule. Following these awards, she holds 452,667 shares of common stock directly and 655,540 shares indirectly through SQN LLC, where she and her spouse are managing members and she disclaims beneficial ownership except for any pecuniary interest.
Madrigal Pharmaceuticals director Richard S. Levy received new equity awards. He was granted 454 shares of common stock as restricted stock units and 766 stock options with an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he continues in service. After the grants, he directly owns 22,469 common shares.
Madrigal Pharmaceuticals director Jacqualyn A. Fouse reported receiving new equity awards. She was granted 454 shares of common stock in the form of restricted stock units at no cost, increasing her direct common stock holdings to 1,551 shares.
She was also granted stock options covering 766 shares of common stock at an exercise price of $499.86 per share, expiring on June 17, 2036. Both the restricted stock units and the options vest 100% on the earlier of June 17, 2027 or the company’s 2027 annual meeting of stockholders, provided she continues in service with Madrigal through that date.
Madrigal Pharmaceuticals director James M. Daly reported awards of company equity as part of his compensation. He received 454 restricted stock units, which represent an equivalent number of common shares when they vest. He was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share.
Both the restricted stock units and the option vest 100% on the earlier of June 17, 2027 or the date of Madrigal’s 2027 annual meeting of stockholders, as long as he continues in service with the company. Following the grant, Daly directly holds 3,081 shares of common stock and the newly granted option on 766 shares.
Madrigal Pharmaceuticals director Daniel J. Brennan reported equity compensation awards. He received 404 shares of Common Stock as restricted stock units and a stock option for 681 shares at an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he remains in service. After these grants, Brennan directly holds 1,371 Common shares and 681 option shares.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Madrigal Pharmaceuticals reported equity compensation awards related to board service by representatives of Baker Bros.-affiliated funds. On June 17, 2026, a total of 908 restricted stock units (RSUs) and 1,532 non-qualified stock options tied to Madrigal common stock were granted in the aggregate to Julian C. Baker and Dr. Raymond Cheong, who serve on the board as representatives of 667, L.P. and Baker Brothers Life Sciences, L.P. The stock options have a strike price of $499.86, fully vest on the earlier of June 17, 2027 or the 2027 annual stockholder meeting, and expire 10 years from grant. The filing explains that the Baker funds have an indirect proportionate pecuniary interest in these securities, the investment adviser has voting and dispositive power, and various Baker entities disclaim beneficial ownership except to the extent of their pecuniary interest. No open-market purchases or sales are reported; all transactions are classified as grants or awards.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel reported an open-market sale of 1,042 shares of the company’s Common Stock on June 1, 2026 at an average price of $495.74 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 2, 2026, indicating it was pre-arranged. Following this sale, Soergel directly holds 10,033 shares of Madrigal Pharmaceuticals common stock.
Madrigal Pharmaceuticals director Richard S. Levy sold 5,682 shares of common stock in a series of open-market transactions on May 22, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2026, at weighted average prices between about $506.42 and $520.28 per share. Following these transactions, he directly holds 22,015 shares of Madrigal common stock.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel reported an automatic tax-related share sale. The company sold 844 shares of common stock on his behalf at an average price of $515.90 per share to cover tax withholding obligations from vesting restricted stock units. After this transaction, he directly holds 11,075 shares, and the sale was not made at his discretion.
Madrigal Pharmaceuticals EVP and CFO Mardi Dier reported both stock sales and new equity awards. On March 6, 2026, she sold a total of 1,982 shares of common stock in multiple open-market transactions at prices generally in the low-to-mid $400s per share. One sale was made by the company to cover tax withholding on vesting restricted stock units, and certain sales were made under a pre-established Rule 10b5-1 trading plan adopted on September 2, 2025.
On March 4, 2026, she received 5,215 restricted stock units and an option for 6,519 shares. The restricted stock units vest in four equal annual installments on March 4 of 2027, 2028, 2029, and 2030, while the option vests 25% on March 4, 2027, with the remainder vesting 6.25% at the end of each following three-month period, subject to continued service.
Madrigal Pharmaceuticals President and CEO William John Sibold reported a mix of equity grants and a small share sale. On March 4, 2026, he received 18,743 stock options and 14,995 restricted stock units, both granted at $0.0000 per share and scheduled to vest in installments through 2030 subject to continued service.
On March 6, 2026, 1,663 shares of common stock were sold at an average price of $431.94 per share. According to the disclosure, this sale was executed by Madrigal Pharmaceuticals on Sibold’s behalf solely to cover tax withholding obligations tied to restricted stock unit vesting and was automatic rather than at his discretion. After these transactions, he directly held 161,829 shares of common stock and 18,743 stock options.
Madrigal Pharmaceuticals’ general counsel Kelley Shannon reported a mix of equity awards and a small share sale. On March 4, 2026, she received 4,017 shares of common stock as a grant of restricted stock units that vest in four equal annual installments on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, contingent on continued service. She was also granted a stock option for 5,022 shares that vests 25% on March 4, 2027 and 6.25% every three months thereafter, also subject to continued service. On March 6, 2026, 360 shares of common stock were sold at $431.94 per share by the company on her behalf solely to cover tax withholding from RSU vesting, an automatic transaction, leaving her with 12,138 shares of common stock held directly.
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman reported a mix of stock compensation activity and a small tax-related sale. On March 6, 2026, 419 shares of common stock were sold at $431.94 per share to cover tax withholding tied to restricted stock unit vesting; this sale was executed automatically by the company and not at her discretion.
On March 4, 2026, she received 3,989 shares of common stock as a restricted stock unit grant and 4,986 stock options. The restricted stock units vest in four equal annual installments on March 4 of 2027, 2028, 2029 and 2030, contingent on continued service. The stock options vest 25% on March 4, 2027, then 6.25% at the end of each following three‑month period, also subject to continued service.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of common stock tied to tax withholding. On the reported date, 491 shares of Madrigal Pharmaceuticals common stock were sold at an average price of $431.94 per share to cover tax obligations from vesting restricted stock units. After this transaction, Taub directly held 452,213 shares of common stock. She also reported indirect ownership of 655,540 shares held by SQN LLC, where she and her spouse are managing members, while disclaiming beneficial ownership of those shares beyond any pecuniary interest.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel received new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted options for 5,467 shares at an exercise price of $0.00 per share and 4,374 shares of common stock as a restricted stock unit award.
The restricted stock units vest in four equal installments of 25% on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, if he remains in service on each date. The option vests 25% on March 4, 2027, with an additional 6.25% vesting on the last day of each successive three‑month period, also subject to continued service. Following these grants, he directly holds 11,919 shares of common stock.
Madrigal Pharmaceuticals EVP and CFO Mardi Dier had 1,183 shares of common stock sold at an average price of $427.21 per share. The shares were sold by the company on her behalf solely to cover tax withholding on vested restricted stock units, in an automatic, non-discretionary transaction. After this sale, she continues to hold 9,257 shares directly.
Madrigal Pharmaceuticals director Richard S. Levy exercised stock options for 2,500 shares of common stock. The derivative transaction converted a fully vested stock option into 2,500 common shares at a price of $7.36 per share. Following this exercise, Levy directly owns 27,697 shares of Madrigal common stock.
Madrigal Pharmaceuticals director Richard S. Levy reported an option exercise and share acquisition. On January 26, 2026, he exercised a stock option for 4,000 shares of Madrigal common stock at an exercise price of $16.46 per share. The option was fully vested and exercisable. Following this transaction, Levy directly owns 25,197 shares of Madrigal common stock, and the reported stock option position was reduced to 0 derivative securities.
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman reported routine share sales. On January 26, 2026, a total of 910 shares of Madrigal common stock were sold in two transactions at prices of $492.42 for 340 shares and $494.59 for 570 shares.
The filing explains that 340 shares were sold by the company on her behalf solely to cover tax withholding tied to vesting restricted stock units and occurred automatically. The 570-share sale was executed under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2024. Following these transactions, Huntsman directly beneficially owns 9,122 shares of Madrigal common stock.
Madrigal Pharmaceuticals President and CEO William John Sibold reported an automatic sale of company stock related to taxes. On January 26, 2026, 1,577 shares of Madrigal common stock were sold at $492.42 per share. According to the filing, the issuer sold these shares on his behalf solely to cover tax withholding tied to the vesting of restricted stock units, and the sale was not at his discretion. After this transaction, Sibold directly beneficially owned 148,497 shares of Madrigal common stock.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of common stock related to taxes on equity compensation. On January 26, 2026, the issuer sold 647 shares of Madrigal common stock on her behalf at $492.42 per share to cover tax withholding obligations from the vesting of restricted stock units. The filing states this sale was automatic and not at her discretion.
After this transaction, Taub beneficially owned 452,704 shares directly and 655,540 shares indirectly through SQN LLC. She and her spouse are managing members of SQN LLC, and she disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals’ General Counsel reports two stock sales. Kelley Shannon T, an officer of Madrigal Pharmaceuticals, reported selling 263 shares of common stock at $490.77 per share and 429 shares at $501.40 per share on 01/20/2026. The first transaction reflects shares sold by the company on the reporting person’s behalf solely to cover tax withholding tied to vesting restricted stock units and occurred automatically. The second sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2024. After these transactions, the reporting person directly owned 8,481 shares of Madrigal common stock.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of company stock primarily to cover taxes. On January 20, 2026, the issuer sold 2,238 shares of common stock on her behalf at $490.77 per share to satisfy tax withholding obligations tied to vesting restricted stock units, a process described as automatic and not at her discretion. Following this transaction, she directly held 453,351 shares of Madrigal Pharmaceuticals common stock. The filing also notes an additional 655,540 shares held indirectly through SQN LLC, an entity managed by Taub and her spouse, with Taub disclaiming beneficial ownership of those securities except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals’ Chief Accounting Officer Rita Thakkar reported new equity awards. On January 15, 2026, she received 2,398 shares of common stock as a grant of restricted stock units at no cost. These units vest in four equal 25% installments on January 15 of 2027, 2028, 2029 and 2030, as long as she remains in service with the company on each vesting date.
She was also granted a stock option for 1,826 shares of common stock, likewise at no cost on the grant date. The option vests 25% of the shares on January 15, 2027, with the remaining 75% vesting in 6.25% increments on the last day of each successive three-month period, subject to continued service. After these grants, she directly holds 2,398 shares of common stock and 1,826 stock options.
Madrigal Pharmaceuticals director Paul A. Friedman reported an option exercise and small share sale. On January 9, 2026, he exercised a stock option for 280 shares of common stock at $15.80 per share, then sold 280 shares of common stock at a weighted average price of $551.2414 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, he directly owned 187,164 shares of Madrigal common stock. The filing also notes 655,540 shares held indirectly through SQN LLC, an entity for which he and his spouse are managing members, with a disclaimer that he only benefits to the extent of his pecuniary interest.
Madrigal Pharmaceuticals director Paul A. Friedman reported insider transactions in company common stock. On January 9, 2026, he exercised a fully vested stock option for 24,520 shares of common stock at an exercise price of $15.8 per share and then sold multiple small blocks of common stock the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025. The reported sale prices are disclosed as weighted averages, with underlying trades occurring at prices generally ranging from about $511.71 to $545.79 per share. After these transactions, he directly held 187,164 shares of common stock and 280 stock options, and also reported 655,540 shares held indirectly through SQN LLC, for which he and his spouse are managing members.
Madrigal Pharmaceuticals director Rebecca Taub reported stock transactions dated 01/09/2026. She exercised a stock option for 240 shares of common stock at $15.80 per share and then sold 40 shares at $545.79 and 200 shares at a weighted average price of $551.242. These sales were made under a Rule 10b5-1 trading plan adopted on September 10, 2025. After the reported sales, she directly owned 455,589 shares of common stock. The filing also lists 655,540 shares held indirectly by SQN, LLC, an entity for which she and her spouse are managing members, and she disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals director Rebecca Taub reported an insider transaction involving stock options and common shares of Madrigal Pharmaceuticals, Inc. (MDGL) dated 01/09/2026. She exercised a stock option for 18,410 shares of common stock at an exercise price of $15.8 per share and acquired the same number of common shares.
On the same date, she then sold Madrigal common stock in numerous open-market transactions under a Rule 10b5-1 trading plan, at weighted-average prices disclosed in ranges from $511.71 to $539.44 per share. After these trades, she held 455,589 shares of common stock directly and 655,540 shares indirectly through SQN, LLC, where she and her spouse are managing members, while disclaiming beneficial ownership beyond any pecuniary interest.
Madrigal Pharmaceuticals disclosed an insider transaction by a company director on December 10, 2025. The director acquired 24,800 shares of common stock at $15.8 per share and, on the same day, sold 24,800 shares in multiple open-market trades at weighted average prices described in several ranges between approximately $547 and $555, all under a Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, the director beneficially owned 187,164 shares directly and 655,540 shares indirectly through SQN LLC, where the director and spouse are managing members and disclaim beneficial ownership beyond any pecuniary interest.
Madrigal Pharmaceuticals director reported several stock transactions dated 12/10/2025. The reporting person exercised a stock option to acquire 18,650 shares of common stock at $15.8 per share, then sold multiple blocks of shares the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025 at weighted-average prices reported between $547.16 and $555.31 per share, plus an additional sale at $555.39 per share.
The reporting person also made a charitable contribution of 5,455 shares of common stock to a donor advised fund. After these transactions, they held 455,589 shares directly and 655,540 shares indirectly through SQN LLC, where the reporting person and a spouse are managing members, with beneficial ownership of those indirect shares disclaimed except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals (MDGL) reported that its Chief Commercial Officer filed a Form 4 disclosing multiple sales of common stock on 11/21/2025. One sale of 894 shares was made by the company on the officer’s behalf to cover tax withholding tied to vesting of restricted stock units and was automatic, not at the officer’s discretion. Additional market sales were executed the same day in small blocks under a Rule 10b5-1 trading plan adopted on November 5, 2024, at weighted average prices generally between about $547 and $565 per share. Following these transactions, the officer directly beneficially owned 10,032 shares of Madrigal common stock.
Madrigal Pharmaceuticals (MDGL) reported insider activity by a director on 11/13/2025. The filing shows two option exercises and subsequent open‑market sales executed under a Rule 10b5‑1 trading plan adopted on August 14, 2025.
The director exercised stock options for 2,500 shares at an exercise price of $7.36 and 6,000 shares at $16.46. Following the exercises, multiple sales occurred the same day across several tranches at weighted average prices, with disclosed ranges from $514.03 to $528.94 per share. After these transactions, the filing lists 21,197 shares of common stock beneficially owned on a direct basis.
The option entries indicate the underlying shares were fully vested and exercisable. Price footnotes state each reported sale price is a weighted average, with full trade‑level details available upon request.
Madrigal Pharmaceuticals (MDGL) director reported option exercises and share sales. On 11/05/2025, the insider exercised stock options for 5,470 shares at $9.45, 10,000 shares at $303.79, and 1,105 shares at $280.04 (all fully vested). The insider then sold multiple blocks of common stock, with weighted-average sale prices ranging from about $480.2397 to $490.9817, as detailed in footnotes. After these transactions, the insider directly beneficially owned 2,627 shares.